`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`ARGENTUM PHARMACEUTICALS LLC
`Petitioner
`v.
`
`ICOS CORPORATION,
`Patent Owner
`
`U.S. Patent No. 6,943,166 B1
`Inter Partes Review No. IPR2017-01762
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`JOINT MOTION TO KEEP CONFIDENTIAL AND SEPARATE
`UNDER 35 U.S.C. § 317(b) AND 37 C.F.R. § 42.747(c)
`
`
`
`Joint Motion to Keep Confidential and Separate, IPR2017-01762
`U.S. Patent No. 6,943,166
`
`
`Pursuant to 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74(c), Petitioner and
`
`Patent Owner jointly request to file EX1039, the settlement agreement between the
`
`parties, as referenced in the Joint Motion to Terminate, as business confidential
`
`information, and to have it be kept separate from the file of the involved patent.
`
`The Parties sought, and received, authorization via email from the Board to file this
`
`motion on August 25, 2017.
`
`If requested, the rules permit the Parties to have any filed settlement
`
`agreement treated as business confidential information and kept separate from the
`
`files of the involved patent. 37 C.F.R. § 42.74(c). Indeed, the statute requires it. 35
`
`U.S.C. § 317(b).
`
`The Parties hereby request that the settlement agreement filed herewith as
`
`Exhibit 1039 be treated as business confidential information, be kept separate from
`
`the file of the above captioned IPR, and be made available only to Federal
`
`Government agencies on written request, or to any person on a showing of good
`
`cause pursuant to 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74(c). In view of that
`
`request the settlement agreement has been filed for access by the “Parties and Board
`
`Only.”
`
`
`
`
`
`
`
`
`
`-2-
`
`
`
`Joint Motion to Keep Confidential and Separate, IPR2017-01762
`U.S. Patent No. 6,943,166
`
`
`Respectfully submitted,
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Date: Aug. 28, 2017
`
`
`
`/Kevin B. Laurence/
`
`Kevin B. Laurence
`Lead Counsel for Petitioner
`Registration No. 38,219
`klaurence@lpiplaw.com
`
`Laurence & Phillips IP Law LLP
`1940 Duke St., Ste. 200
`Alexandria, Virginia 22314
`Telephone: 703-448-8787
`
`
`/Mark J. Feldstein/
`
`Mark J. Feldstein
`Lead Counsel for Patent Owner
`Registration No. 46,693
`mark.feldstein@finnegan.com
`
`Finnegan, Henderson, Farabow, Garrett &
`Dunner, LLP
`901 New York Avenue, NW
`Washington, DC 20001-4413
`Telephone: 202-408-4092
`
`
`
`
`
`
`-3-
`
`
`
`Joint Motion to Keep Confidential and Separate, IPR2017-01762
`U.S. Patent No. 6,943,166
`
`
`CERTIFICATE OF SERVICE
`
`
`
`Pursuant to 37 C.F.R. §§ 42.6(e) and 42.105, the undersigned certifies that
`
`on Aug. 26, 2017, a complete copy of the foregoing Joint Motion to Keep
`
`Confidential was served on patent owner’s counsel of record via e-mail, as agreed
`
`to by counsel, as follows:
`
`Mark J. Feldstein
`Joshua L. Goldberg
`Yieyie Yang
`Maureen D. Queler
`Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
`901 New York Avenue, NW
`Washington, DC 20001-4413
`Email: mark.feldstein@finnegan.com
`Email: joshua.goldberg@finnegan.com
`Email: yieyie.yang@finnegan.com
`Email: maureen.queler@finnegan.com
`
`
`
`Mark J. Stewart
`Dan L. Wood
`Gerald P. Keleher
`Eli Lilly and Company
`Lilly Corporate Center
`Indianapolis, IN 46285
`Email: stewart_mark@lilly.com
`Email: wood_dan_l@lilly.com
`Email: keleher_gerald@lilly.com
`
`
`
`
`
`
`
`
`Dated: August 28, 2017
`
`
`
`
`
`Respectfully submitted,
`
`/Kevin B. Laurence/
`Kevin B. Laurence, Lead Counsel for Petitioner
`Registration No. 38,219
`
`
`
`
`
`-4-
`
`